BACKGROUND: Deficiency of vitamin D is commonly associated with hip fracture and treatment with vitamin D reduces hip fracture rates. Consequently, the demand for assays to measure 25-hydroxyvitamin D (25-OHD) has increased. The Nichols Advantage chemiluminescence protein-binding assay (CLPBA) for 25-OHD is a first-generation automated immunoassay with decreased turnaround time, reduced manual handling and non-radioactive label. METHODS: We compared the CLPBA to the DiaSorin radioimmunoassay (RIA) and high-performance liquid chromatography (HPLC) for the measurement of 25-OHD using 161 samples from hip fracture patients and samples before and after institution of ergocalciferol (vitamin D(2)) therapy. RESULTS: A negative bias for the CLPBA at concentrations below 30 nmol/L and a positive bias at 25-OHD values above 30 nmol/L compared with the RIA resulted in diagnostic discordance for one in three samples when using 30 and 50 nmol/L as decision limits. HPLC analysis confirmed the presence of a negative bias for the CLPBA at low values. Both immunoassays under-estimate 25-hydroxyvitamin D(2). CONCLUSIONS: The discordance between 25-OHD values may be due to differences in standardization of each assay relative to HPLC. Our results emphasize the need for assay-specific clinical decision limits.
BACKGROUND: Deficiency of vitamin D is commonly associated with hip fracture and treatment with vitamin D reduces hip fracture rates. Consequently, the demand for assays to measure 25-hydroxyvitamin D (25-OHD) has increased. The Nichols Advantage chemiluminescence protein-binding assay (CLPBA) for 25-OHD is a first-generation automated immunoassay with decreased turnaround time, reduced manual handling and non-radioactive label. METHODS: We compared the CLPBA to the DiaSorin radioimmunoassay (RIA) and high-performance liquid chromatography (HPLC) for the measurement of 25-OHD using 161 samples from hip fracturepatients and samples before and after institution of ergocalciferol (vitamin D(2)) therapy. RESULTS: A negative bias for the CLPBA at concentrations below 30 nmol/L and a positive bias at 25-OHD values above 30 nmol/L compared with the RIA resulted in diagnostic discordance for one in three samples when using 30 and 50 nmol/L as decision limits. HPLC analysis confirmed the presence of a negative bias for the CLPBA at low values. Both immunoassays under-estimate 25-hydroxyvitamin D(2). CONCLUSIONS: The discordance between 25-OHD values may be due to differences in standardization of each assay relative to HPLC. Our results emphasize the need for assay-specific clinical decision limits.
Authors: M Z Erkal; J Wilde; Y Bilgin; A Akinci; E Demir; R H Bödeker; M Mann; R G Bretzel; H Stracke; M F Holick Journal: Osteoporos Int Date: 2006-05-23 Impact factor: 4.507
Authors: Zhican Wang; Tauri Senn; Tom Kalhorn; Xi Emily Zheng; Songmao Zheng; Connie L Davis; Mary F Hebert; Yvonne S Lin; Kenneth E Thummel Journal: Anal Biochem Date: 2011-07-13 Impact factor: 3.365
Authors: Helen M Pappa; Catherine M Gordon; Tracee M Saslowsky; Anna Zholudev; Brian Horr; Mei-Chiung Shih; Richard J Grand Journal: Pediatrics Date: 2006-11 Impact factor: 7.124
Authors: Emily M Stein; Adi Cohen; Matthew Freeby; Halley Rogers; Shannon Kokolus; Vanessa Scott; Donna Mancini; Susan Restaino; Robert Brown; Donald J McMahon; Elizabeth Shane Journal: Clin Transplant Date: 2009-04-23 Impact factor: 2.863
Authors: E Cavalier; E Rozet; R Gadisseur; A Carlisi; M Monge; J-P Chapelle; P Hubert; J-C Souberbielle; P Delanaye Journal: Osteoporos Int Date: 2009-09-09 Impact factor: 4.507